<DOC>
	<DOC>NCT00004654</DOC>
	<brief_summary>OBJECTIVES: I. Evaluate migraine prophylaxis with soy protein isolate in patients with hereditary hemorrhagic telangiectasia. II. Assess whether soy protein isolate reduces the frequency and severity of epistaxis and gastrointestinal bleeding in these patients.</brief_summary>
	<brief_title>Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized study. One group of patients is treated with soy protein isolate for 12 weeks. The control group receives a placebo for 12 weeks. Patients cross to the alternate group following a 4-week washout.</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Telangiectasia, Hereditary Hemorrhagic</mesh_term>
	<criteria>Hereditary hemorrhagic telangiectasia (HHT) with 2 of the following: Firstdegree relative with HHT History of recurrent epistaxis or gastrointestinal bleeding Three or more skin telangiectasia Migraine headache meeting International Headache Society criteria 3 or more times a month for more than 1 year No pattern of daily headaches No severe head trauma No onset of headaches after 50 years of age At least 1 month since migraine prophylaxis At least 1 month since any of the following medications: Beta blockers; Calcium channel blockers; Divalproex sodium; Tricyclic antidepressants; Selective serotonin reuptake inhibitors Concurrent regular treatment for migraine and gastrointestinal hemorrhage allowed Creatinine no greater than 2.5 g/dL No allergy to soy No pregnant women No women with intent to become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>genetic diseases and dysmorphic syndromes</keyword>
	<keyword>hematologic disorders</keyword>
	<keyword>hereditary hemorrhagic telangiectasia</keyword>
	<keyword>rare disease</keyword>
</DOC>